| Expression pattern: |
UP |
| Associated gene: |
ASF1B, PI3K/AKT/mTOR (PAM) signaling |
| Associated microRNA: |
miR-300 |
| Biological function: |
promotes cisplatin (DDP) resistance, migration and invasion, and inhibits apoptosis in TNBC cells |
| Molecular mechanism: |
Acts as a ceRNA sponging miR-300 to upregulate ASF1B, which activates PI3K/AKT/mTOR signaling and enhances cisplatin resistance |
| Biological pathway or process: |
PI3K/AKT/mTOR (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); chemoresistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; Transfection; CCK8; Wound Healing Assay; Transwell Assay; TUNEL; Western Blot; Clinical Sample Validation; RNA-seq |
| Clinical significance: |
circUBAP2 could act as a potential biomarker to enhance the sensitivity of TNBC cells to DDP therapies |
| Description: |
circUBAP2 is upregulated in TNBC, especially in cisplatin-resistant (DDP-resistant) cells, and its knockdown sensitizes TNBC cells to DDP. Mechanistically, circUBAP2 sponges miR-300 to increase ASF1B expression, thereby activating PI3K/AKT/mTOR signaling and promoting chemoresistance and malignant phenotypes. |
| Confidence score: |
0.753 |